Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 9 April 2009, doi:10.1136/bmj.b1085
Cite this as: BMJ 2009;338:b1085
UK pilots will assess provider initiated "opt-out" testing strategies
| The first 150 words of the full text of this article appear below. |
The case for early diagnosis of HIV is compelling. Early treatment of HIV (when CD4+ cells are still >200/µl) has several benefits, both for the individual and for public health—it reduces associated morbidity and mortality and greatly reduces the potential for onward HIV transmission.1 Self awareness of HIV seropositivity can be a powerful prevention tool at an individual and community level. Evidence suggests that some people with HIV behave in a less risky manner shortly after they learn they are HIV positive.2 Early diagnosis and treatment is also cost effective, with direct care costs for late presenters (CD4+ cells <200/µl) estimated to be 200% higher than for early presenters.3
Despite medical advances in diagnosing and treating HIV, many people still present late with HIV infection.4 In 2005, about 20 000 residents of the United Kingdom were unaware that they were infected with HIV; almost half of them were men who
Gavin Bryce, strategic lead, HIV prevention and sexual health
1 Brighton and Hove City Teaching Primary Care Trust, Integrated Public Health Team, Brighton BN1 6AG
Gavin.Bryce@bhcpct.nhs.uk
Read all Rapid Responses